11 research outputs found
Co-infection associated with SARS-CoV-2 and their management
SARS-CoV-2 was discovered in Wuhan, China and quickly spread throughout the world. This deadly virus moved from person to person, resulting in severe pneumonia, fever, chills and hypoxia. Patients are still experiencing problems after recovering from COVID-19. This review covers COVID-19 and associated issues following recovery from COVID-19, as well as multiorgan damage risk factors and treatment techniques. Several unusual illnesses, including mucormycosis, white fungus infection, happy hypoxia and other systemic abnormalities, have been reported in recovered individuals. In children, multisystem inflammatory syndrome with COVID-19 (MIS-C) is identified. The reasons for this might include uncontrollable steroid usage, reduced immunity, uncontrollable diabetes mellitus and inadequate care following COVID-19 recovery
Recommended from our members
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury Cases
Introduction
Drug-induced acute kidney injury (DI-AKI) is a frequent adverse event. The identification of DI-AKI is challenged by competing etiologies, clinical heterogeneity among patients, and a lack of accurate diagnostic tools. Our research aims to describe the clinical characteristics and predictive variables of DI-AKI.
Methods
We analyzed data from the DIRECT study (NCT02159209), an international, multi-center, observational cohort study of enriched clinically adjudicated DI-AKI cases. Cases met the primary inclusion criteria if the patient was exposed to at least one nephrotoxic drug for a minimum of 24 hours prior to acute kidney injury (AKI) onset. Cases were clinically adjudicated and inter-rater reliability (IRR) was measured using Krippendorff's alpha. Variables associated with DI-AKI were identified using L1 regularized multivariable logistic regression. Model performance was assessed using the area under the receiver operating characteristic curve (ROC AUC).
Results
314 AKI cases met the eligibility criteria for this analysis, and 271 (86%) cases were adjudicated as DI-AKI. The majority of the AKI cases were recruited from the United States (68%). The most frequent causal nephrotoxic drugs were vancomycin (48.7%), non-steroidal anti-inflammatory drugs (18.2%), and piperacillin/tazobactam (17.8%). The IRR for DI-AKI adjudication was 0.309. The multivariable model identified age, vascular capacity, hyperglycemia, infections, pyuria, serum creatinine trends, and contrast media as significant predictors of DI-AKI with good performance, ROC AUC 0.86.
Conclusions
The identification of DI-AKI is challenging even with comprehensive adjudication by experienced nephrologists. Our analysis identified key clinical characteristics and outcomes of DI-AKI compared to other AKI etiologies
CD13 facilitates immune cell migration and aggravates acute injury but promotes chronic post-stroke recovery
Abstract Introduction Acute stroke leads to the activation of myeloid cells. These cells express adhesion molecules and transmigrate to the brain, thereby aggravating injury. Chronically after stroke, repair processes, including angiogenesis, are activated and enhance post-stroke recovery. Activated myeloid cells express CD13, which facilitates their migration into the site of injury. However, angiogenic blood vessels which play a role in recovery also express CD13. Overall, the specific contribution of CD13 to acute and chronic stroke outcomes is unknown. Methods CD13 expression was estimated in both mice and humans after the ischemic stroke. Young (8–12 weeks) male wild-type and global CD13 knockout (KO) mice were used for this study. Mice underwent 60 min of middle cerebral artery occlusion (MCAO) followed by reperfusion. For acute studies, the mice were euthanized at either 24- or 72 h post-stroke. For chronic studies, the Y-maze, Barnes maze, and the open field were performed on day 7 and day 28 post-stroke. Mice were euthanized at day 30 post-stroke and the brains were collected for assessment of inflammation, white matter injury, tissue loss, and angiogenesis. Flow cytometry was performed on days 3 and 7 post-stroke to quantify infiltrated monocytes and neutrophils and CXCL12/CXCR4 signaling. Results Brain CD13 expression and infiltrated CD13+ monocytes and neutrophils increased acutely after the stroke. The brain CD13+lectin+ blood vessels increased on day 15 after the stroke. Similarly, an increase in the percentage area CD13 was observed in human stroke patients at the subacute time after stroke. Deletion of CD13 resulted in reduced infarct volume and improved neurological recovery after acute stroke. However, CD13KO mice had significantly worse memory deficits, amplified gliosis, and white matter damage compared to wild-type animals at chronic time points. CD13-deficient mice had an increased percentage of CXCL12+cells but a reduced percentage of CXCR4+cells and decreased angiogenesis at day 30 post-stroke. Conclusions CD13 is involved in the trans-migration of monocytes and neutrophils after stroke, and acutely, led to decreased infarct size and improved behavioral outcomes. However, loss of CD13 led to reductions in post-stroke angiogenesis by reducing CXCL12/CXCR4 signaling
Challenges and progress in nose-to-brain drug delivery
Numerous diseases have been found to be associated with the central nervous system (CNS). The traditional oral and intravenous methods of treatment have several limitations, resulting in poor therapeutic outcomes for such illnesses. The intranasal (IN) route is a relatively simple and noninvasive pathway for rapid drug administration directly into the CNS. This route, known as the nose-to-brain (NtB) pathway, exploits brain and nasal cavity connectivity through olfactory and trigeminal nerves, circumventing systemic circulation. Administering drugs via this route can bypass the blood-brain barrier (BBB) and reduce the number of drug moieties distributed to nontarget organs, giving the advantages of minimal dose reduction, no systemic dilution, and avoiding first-pass hepatic metabolism. The NtB delivery system can achieve a higher brain/blood drug concentration ratio by several-fold and has been extensively studied to deliver drugs targeted for CNS disorders. Despite these advantages, delivering drugs to the CNS through the nasal cavity is challenging due to anatomical (access to the olfactory and trigeminal nerve), physiological (mucociliary clearance, nasal cavity environment), and formulation (drug loading, delivery volume, delivery efficiency) factors. Interdisciplinary research has been conducted to overcome these challenges. The pursuits in this field include better design of applicators to allow precise delivery of the dosage forms, the engineering of mucoretentive vehicles and materials to overcome nasal clearance, and utilization of different micro and nanocarriers to increase delivery efficiency and to provide protection for drug molecules susceptible to chemical or metabolic degradation. Moreover, 3D printing techniques have been employed to aid this delivery system’s future design and development. Promising progress has been made, pushing these novel technologies further down the research pipeline and clinical translation.<br/